Acrivon Therapeutics, INC Form 4 insider transactions

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, was granted stock options for 67,567 shares on March 1, 2024.

Acrivon Therapeutics' Chief Financial Officer, Rasmus Holm-Jorgensen, was granted stock options for 90,090 shares on March 1, 2024.

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, was granted stock options for 45,045 shares on March 1, 2024.

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, was granted stock options for 90,090 shares at an exercise price of $5.70 on March 1, 2024.

Acrivon Therapeutics' CEO and EVP of Business Operations were granted stock options, with vesting schedules tied to continued service.

Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, and EVP of Business Operations, Kristina Masson, reported transactions involving company stock, including shares withheld for tax obligations and indirect holdings.

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, sold 99 shares of common stock to cover tax obligations related to vesting restricted stock units.

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, sold 184 shares of common stock to cover tax obligations related to vesting restricted stock units.

Acrivon Therapeutics' Chief Financial Officer, Rasmus Holm-Jorgensen, sold 368 shares of common stock to cover tax obligations related to vesting restricted stock units.

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, sold 402 shares of common stock to cover tax obligations related to vesting restricted stock units.

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, sold 613 shares of common stock to cover tax obligations related to vesting restricted stock units.

Acrivon Therapeutics' CEO and EVP reported the withholding of shares to cover tax obligations related to vesting restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Acrivon Therapeutics' CEO and EVP report changes in their beneficial ownership of common stock due to tax withholding upon vesting of restricted stock units.

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposal of 184 common stock shares to cover tax obligations upon vesting of restricted stock units.

Kristina Masson, EVP of Business Operations at Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reports disposition of shares to cover tax obligations upon vesting of restricted stock units.

Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Peter Blume-Jensen, CEO of Acrivon Therapeutics, reports the disposal of shares to cover tax obligations upon vesting of restricted stock units.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

RA Capital Management and related entities report the acquisition of stock options in Acrivon Therapeutics, Inc. on June 20, 2024.

Director Michael Tomsicek acquired 20,275 stock options in Acrivon Therapeutics on June 20, 2024.

Director Sharon Shacham acquired 20,275 stock options in Acrivon Therapeutics on June 20, 2024.

Director Derek DiRocco acquired stock options in Acrivon Therapeutics, but disclaims beneficial ownership due to an arrangement with RA Capital Management.

Charles M. Baum, a director of Acrivon Therapeutics, acquired 20,275 stock options on June 20, 2024, at an exercise price of $6.52.

Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, exercised stock options to acquire 10,000 shares of common stock at $1.04 per share on May 17, 2024.

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports a transaction involving the withholding of common stock to cover tax obligations.